JAMA Network
About The Study: In this study, semaglutide for the secondary prevention of cardiovascular disease was effective but meeting conventional cost-effectiveness thresholds will require additional price reductions.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
